The RAPS learning platform provider will be upgrading its security posture. This will take the system off-line from 20 July through the end of the day 23 July. This will affect any Online Course, eBook, and Virtual Program Attendance. Thank you for your patience.
Draft Guidance for Nitroglycerin, Rifaximin Products Released by FDA
Posted 13 February 2012 | By
The US Food and Drug Administration (FDA) released new draft guidance documents on 13 February covering rifaximin tablets, nitroglycerin metered spray/sublingual products and nitroglycerin metered aerosol/sublingual products.
The draft guidances cover bioequivalence (BE) recommendations for both nitroglycerin and rifaximin products, particularly BE testing used to support Abbreviated New Drug Applications (ANDAs).
The draft guidances for nitroglycerin products are "revised versions of previously published draft guidances on the subject," while the rifaximin guidance is brand new.
Comments on the draftguidances are due before 13 April, 2012.